Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTAW) Gross Profit (2021 - 2025)

Historic Gross Profit for Strata Critical Medical (SRTAW) over the last 5 years, with Q3 2025 value amounting to $11.6 million.

  • Strata Critical Medical's Gross Profit rose 5468.83% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year increase of 7593.87%. This contributed to the annual value of $58.9 million for FY2024, which is 3987.7% up from last year.
  • Latest data reveals that Strata Critical Medical reported Gross Profit of $11.6 million as of Q3 2025, which was up 5468.83% from $17.7 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Gross Profit ranged from a high of $34.3 million in Q4 2024 and a low of $1.5 million during Q1 2021
  • For the 5-year period, Strata Critical Medical's Gross Profit averaged around $9.8 million, with its median value being $9.0 million (2023).
  • Data for Strata Critical Medical's Gross Profit shows a peak YoY increase of 28117.65% (in 2024) and a maximum YoY decrease of 5180.69% (in 2024) over the last 5 years.
  • Strata Critical Medical's Gross Profit (Quarter) stood at $3.9 million in 2021, then grew by 26.24% to $5.0 million in 2022, then skyrocketed by 81.11% to $9.0 million in 2023, then skyrocketed by 281.18% to $34.3 million in 2024, then crashed by 66.18% to $11.6 million in 2025.
  • Its Gross Profit stands at $11.6 million for Q3 2025, versus $17.7 million for Q2 2025 and $12.0 million for Q1 2025.